Author

Geraldine Landers

Observed names: G Landers, G. Landers, Landers, Geraldine

Observed institutions: Real Academia Española, University Hospitals Birmingham NHS Foundation Trust, University of Leicester, Royal Free London NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Hillingdon Hospitals NHS Foundation Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, Oxford Health NHS Foundation Trust, University Hospitals of Leicester NHS Trust, Hillingdon Hospital, University of Oxford, NIHR Leicester Biomedical Research Centre, RESTART, University College London, University of Birmingham, Newcastle University

OpenAlex ID: A5010340094

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

2021 · Rachael A Evans, Hamish J C McAuley, et al. · The Lancet Respiratory Medicine · 672

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

PDF

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

2022 · R A Evans, O C Leavy, et al. · The Lancet Respiratory Medicine · 413

PDF

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

2019 · Rustam Al-Shahi Salman, MS Dennis, et al. · The Lancet · 199

PDF

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

2022 · Felicity Liew, Shubha Talwar, et al. · EBioMedicine · 121

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

2024 · Felicity Liew, Claudia Efstathiou, et al. · Nature Immunology · 107

PDF

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

2019 · Rustam Al-Shahi Salman, David P Minks, et al. · The Lancet Neurology · 94

PDF

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

2023 · Betty Raman, Celeste McCracken, et al. · The Lancet Respiratory Medicine · 57

PDF

Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage

2021 · Rustam Al-Shahi Salman, Martin S. Dennis, et al. · JAMA Neurology · 50

PDF

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

PDF

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

PDF

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

2023 · Callum Jackson, Iain D Stewart, et al. · The Lancet Respiratory Medicine · 35

Accelerated immune ageing is associated with COVID-19 disease severity

2024 · Janet M. Lord, Tonny Veenith, et al. · Immunity & Ageing · 34

PDF

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

2023 · Bang Zheng, Giulia Vivaldi, et al. · The Lancet Regional Health - Europe · 29

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

2023 · Hamish J.C. McAuley, Rachael A. Evans, et al. · EClinicalMedicine · 24

PDF

Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study

2023 · Omer Elneima, Hamish J C McAuley, et al. · International Journal of Epidemiology · 23

PDF

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

2023 · Maxime Taquet, Zuzanna Skorniewska, et al. · Brain Communications · 14

PDF

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

PDF

Long COVID research: an update from the PHOSP-COVID Scientific Summit

2023 · Christopher E Brightling, Rachael A Evans, et al. · The Lancet Respiratory Medicine · 11

PDF

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

Works count: 27

Citation count: 4,115

H-index: 21

I10-index: 24